Resultados da pesquisa - Sachdev Thomas

  • A mostrar 1 - 13 resultados de 13
Refinar resultados
  1. 1
    Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature

    Goblet cell carcinoid of the appendix – diagnostic challenges and treatment updates: a case report and review of the literature Por Gilmore, Gregory, Jensen, Kristin, Saligram, Shreyas, Sachdev, Thomas P., Arekapudi, Subramanyeswara R.

    Publicado em 2018
    Obter o texto integral Obter o texto integral Obter o texto integral
    Text
    Adic. favoritos
    Na minha lista:
  2. 2
    Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

    Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2 Por Rogério Lilenbaum, Rita Axelrod, Sachdev Thomas, Afshin Dowlati, L. Seigel, Donald G. Albert, Karsten Witt, D. Botkin

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  3. 3
    A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

    A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 Por Anne M. Traynor, Ju-Whei Lee, Gerald K. Bayer, John M. Tate, Sachdev Thomas, Miroslaw Mazurczak, David L. Graham, Jill Kolesar, Joan H. Schiller

    Publicado em 2009
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Central Cancer Treatment Group Study N05C5

    Placebo-Controlled Trial to Determine the Effectiveness of a Urea/Lactic Acid–Based Topical Keratolytic Agent for Prevention of Capecitabine-Induced Hand-Foot Syndrome: North Centr... Por Sherry L. Wolf, Rui Qin, Smitha Menon, Kendrith M. Rowland, Sachdev Thomas, Robert Delaune, Diana L. Christian, Eduardo R. Pajon, Daniel Satele, Jeffrey L. Berenberg, Charles L. Loprinzi

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer Por Stephanie L. Hines, Betty A. Mincey, Jeff A. Sloan, Sachdev Thomas, Elaine G. Chottiner, Charles L. Loprinzi, Mark D. Carlson, Philip J. Atherton, Muhammad Salim, Edith A. Perez

    Publicado em 2008
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer Por Suresh S. Ramalingam, Michael L. Maitland, Paul Frankel, Athanassios Argiris, Marianna Koczywas, Barbara J. Gitlitz, Sachdev Thomas, Igor Espinoza‐Delgado, Everett E. Vokes, David R. Gandara, Chandra P. Belani

    Publicado em 2009
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma

    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma Por Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Pam Tse, Elaine Chung, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel

    Publicado em 2023
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium

    Cediranib in patients with malignant mesothelioma: A phase II trial of the University of Chicago Phase II Consortium Por Nicholas Campbell, Rangesh Kunnavakkam, Natasha B. Leighl, Mark Vincent, David R. Gandara, Marianna Koczywas, Barbara J. Gitlitz, Edem Agamah, Sachdev Thomas, Walter M. Stadler, Everett E. Vokes, Hedy L. Kindler

    Publicado em 2012
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)

    Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (... Por Neal Ready, Herbert Pang, Lin Gu, Gregory A. Otterson, Sachdev Thomas, Antonius A. Miller, Maria Q. Baggstrom, Gregory A. Masters, Stephen L. Graziano, Jeffrey Crawford, Jeffrey A. Bogart, Everett E. Vokes

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer

    <i>TP53</i> Gain-of-Function and Non–Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer Por Minggui Pan, Chen Jiang, Pam Tse, Ninah Achacoso, Stacey E. Alexeeff, Aleyda V. Solorzano, Elaine Chung, Wenwei Hu, Thach‐Giao Truong, Amit Arora, Tilak Sundaresan, Jennifer M. Suga, Sachdev Thomas, Laurel A. Habel

    Publicado em 2021
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

    Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexp... Por Martin J. Edelman, Xiaofei Wang, Lydia Hodgson, Richard T. Cheney, Maria Q. Baggstrom, Sachdev Thomas, Ajeet Gajra, Erin M. Bertino, Karen L. Reckamp, Julian R. Molina, Joan H. Schiller, Kisha Mitchell-Richards, Paula N. Friedman, Jon Ritter, Ginger L. Milne, Olwen Hahn, Thomas E. Stinchcombe, Everett E. Vokes

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

    Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial Por Nitin Jain, Emily Curran, Neil M. Iyengar, Ernesto Díaz-Flores, Rangesh Kunnavakkam, Leslie Popplewell, Mark Kirschbaum, Theodore Karrison, Harry P. Erba, Margaret Green, Xavier Poiré, Greg Koval, Kevin Shannon, Poluru L. Reddy, Loren Joseph, Ehab Atallah, Philip A. Dy, Sachdev Thomas, Scott E. Smith, L. Austin Doyle, Walter M. Stadler, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

    Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit Por Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc Matrana, Mark E. Burkard, Eddy S. Yang, William J. Edenfield, Elizabeth Claire Dees, Adedayo A. Onitilo, Michael A. Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin M. Parsons, Timothy R. Wassenaar, Leon C. Hwang, Jennifer M. Suga, Robert D. Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory A. Masters, Sachdev Thomas, Malek M. Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, T. Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: